Active Immunological Profile Is Associated with Systemic Sjögren’s Syndrome

Background The aim of this paper was to study the evolution of primary Sjögren’s syndrome (pSS) immunological profile, its impact on pSS activity and long-term evolution in a bicentric cohort of French patients with pSS ( n  = 445, mean age 53.6 ± 14 years, mean follow-up 76.1 ± 51 months). Methods...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical immunology 2011-10, Vol.31 (5), p.840-847
Hauptverfasser: Martel, Clothilde, Gondran, Guillaume, Launay, David, Lalloué, Fabrice, Palat, Sylvain, Lambert, Marc, Ly, Kim, Loustaud-Ratti, Veronique, Bezanahary, Holly, Hachulla, Eric, Jauberteau, Marie Odile, Vidal, Elisabeth, Hatron, Pierre Yves, Fauchais, Anne Laure
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background The aim of this paper was to study the evolution of primary Sjögren’s syndrome (pSS) immunological profile, its impact on pSS activity and long-term evolution in a bicentric cohort of French patients with pSS ( n  = 445, mean age 53.6 ± 14 years, mean follow-up 76.1 ± 51 months). Methods This is a retrospective cohort study. Results Two hundred twelve patients were Sjögren’s syndrome A (SSA) positive, and 131 were both SSA and Sjögren’s syndrome B (SSB) positive. Sixty-eight patients (15%) had cryoglobulinemia. Active systemic profile (i.e., hypergammaglobulinemia, rheumatoid factor (RF), and anti-Sjögren’s syndrome A (anti-SSA), anti-Sjögren’s syndrome B (anti-SSB) positivity), associated with multisystemic involvement, leads to an increased utilization of corticosteroid and hydroxychloroquine. Multivariate analysis pointed out independent statistical association between hypergammaglobulinemia, anti-SSA, anti-SSB, and RF. Cryoglobulinemia is associated with multi-systemic involvement, lymphoma, and pSS-related death. Conclusion The subset of patients with active immunological profile is characterized by systemic complications leading to immunosuppressive drug utilization and polyclonal B-cell activation profile.
ISSN:0271-9142
1573-2592
DOI:10.1007/s10875-011-9553-3